Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is set to release near-term, near-term lease, a clinical-phase biotechnology company developing Neflamapimod, a product designed to improve synaptic function and potentially treat neurodegenerative disorders like non-fluent primary progressive aphasia (nfvPPA). Early data suggests that Neflamapimod may have a positive impact on patients with low plasma pTau181 levels, providing hope for its future potential in treating age-related neurological conditions.

Bears say

CervoMed is a clinical-stage biotechnology company with a negative outlook due to its low product revenue and high risk factors, such as slow market uptake and potential dilution risk. Despite positive clinical data for their product candidate, Neflamapimod, in the treatment of age-related neurologic disorders, the company's valuation based on a DCF analysis is only $640M, translating to a price target of $25 per share. Furthermore, the company's plans for a pivotal trial in DLB have not yet come to fruition, and they still rely heavily on partnerships for drug development and funding.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Sep 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.